Type of Necrosis Influences Prognosis in Hepatocellular Carcinoma After the First Transarterial Chemoembolization

10 May 2021: Clinical Research

Zhi-Juan Wu ^1BCDE , Yin-Fa Xie ^2B , Xu Chang ^2BCD , Lin Zhang ^2AE* , Hui-Yong Wu ^2B , Ji-Bing Liu ^2B , Jian-Xin Zhang ^2C , Peng Sun ^2C

DOI: 10.12659/MSM.929884

Med Sci Monit 2021; 27:e929884

Table 1 Baseline characteristics of the study population.

	Coagulative necrosis	Liquefactive necrosis	P value
No. of patients	79 (46.2%)	92 (53.8%)

Men	73 (92.4%)	79 (85.9%)	0.225
Women	6 (7.6%)	13 (14.1%)

>60 years	32 (40.5%)	27 (29.3%)	0.148
	47 (59.5%)	65 (70.7%)

>400 ng/ml	47 (59.5%)	50 (54.3%)	0.538
	32 (40.5%)	42 (45.7%)
HBV or HCV	69 (87.3%)	75 (81.5%)	0.401
Liver cirrhosis	38 (48.1%)	45 (48.9%)	1.00

Class B (7–9)	13 (16.5%)	17 (18.5%)	0.841
Class A (5–6)	66 (83.5%)	75 (81.5%)
Total bilirubin (umol/L)	22.63±24.08	23.06±27.73	0.913
Albumin (g/L)	36.71±4.63	36.13±4.02	0.382
Prothrombin time (s)	11.62±1.37	11.42±1.31	0.342
Ascites	0.13±0.34	0.10±0.30	0.554
Hepatic encephalopathy	0	0	-

Stage B	18 (22.8%)	11 (12.0%)	0.068
Stage C	61 (77.2%)	81 (88.0%)
Extrahepatic metastasis	14 (17.7%)	26 (28.3%)	0.147
Intrahepatic vessel invasion	53 (67.1%)	73 (79.3%)	0.082
TACE frequency	8.68±3.97	5.63±3.59	0.000

Systemic therapy	8 (10.1%)	13 (14.1%)	0.513
Local therapy	9 (11.4%)	8 (8.7%)

Dead	70 (88.6%)	79 (85.9%)	0.652
Censored	9 (11.4%)	13 (14.1%)
HBV – hepatitis B virus; HCV – hepatitis C virus; TACE – transarterial chemoembolization.